Pfizer CEO Albert Bourla details $70B US investment in manufacturing and R&D, discussing oncology advancements, the GLP-1 ...
What Albert Bourla said
Written from the verified transcript and checked against it. Every figure links to the moment it was said.
Albert Bourla, Pfizer's chairman and CEO, said the company remains committed to investing in U.S. manufacturing and is one of the biggest suppliers to U.S. hospitals. He called oncology the 'crown jewel' of Pfizer, acknowledging a recent phase three trial setback for a monotherapy but emphasizing 'tremendous successes' and promising results in earlier lines of treatment, with optimism for a positive outcome next year. On primary care, Bourla noted a decline in U.S. vaccinations but said the business is doing well, citing Pfizer's position as the best primary care business in the U.S. for the seventh consecutive year. He highlighted an upcoming once-per-month product launch in 2028, positioning Pfizer to compete with Eli Lilly in the GLP-1 market, stating Pfizer aims to be number one. Bourla described AI as transformational for drug development, predicting disruption and new leaders. He expressed optimism about healthcare price reform, citing bipartisan will and White House commitment.
Key takeaways
Pfizer's oncology portfolio is the 'crown jewel' with 'tremendous successes' despite a recent phase three monotherapy setback.
Pfizer will launch a once-per-month GLP-1 product in 2028, aiming to be number one against Eli Lilly.
Pfizer's primary care business has been the best in the U.S. for the seventh consecutive year.
On his trip to North Dakota. Coming up, meanwhile, U.S. maintaining position globally as a leader in pharmaceutical innovation. Biotech giant Pfizer supporting a $70 billion investment in U.S. manufacturing, research and development, in conjunction with the Trump administration last year, Pfizer committing to cutting prices for drugs, for patients. Joining me in a Fox Business exclusive is the chairman and CEO of Pfizer, Albert. Great to have you back. Thank you very much for being here.
I know your investment into America is critical as we celebrate America's 250th. Tell us what you are doing in terms of manufacturing in America today, as the issue of importing the underlying components of pharmaceutical drugs from China and India remains at issue for so many.
You are right. I have to say Pfizer is a true American company, not only because it was founded here, but because this is where the investments happen most. Manufacturing is happening here. We are one of the biggest suppliers to U.S. hospitals. We will continue investing in America in the years to come.
Yes, Albert. I want your take on where growth comes from at Pfizer. I understand that the oncology portfolio remains one of the biggest drivers of growth. You did have a setback, announcing after close the phase three trial of a monotherapy failed to show significant improvement, which many crumpled. So give a sense of where growth comes from at Pfizer now. Last time we were on together, we talked about that acquisition you made, putting you in the GLP-1 drug race as well.
I think oncology is the crown jewel. We have had tremendous successes so far. That was a setback, disappointing for us, but put things in perspective. That acquisition was the only one that didn't work. We knew it was a long shot, but you need to take long shots when you want to cure cancer. You need to try and invest in things that might not work, which was the case. However, we saw highly promising, very good results when it comes to earlier lines of treatments. It means this is in the second line, they did much, much better than in the pipeline. We are moving the drug in, but ongoing, we are out next year. We are very optimistic this would be positive for the first one.
That is wonderful. I know we are all rooting for you to come up with new innovations, treatments, and perhaps solutions for cancer. Thank you for that. Tell me about the primary care business because, of course, obviously, that business has been weighed down by COVID. Doing mea culpa? How significant is the decline in terms of U.S. vaccinations?
There was a decline. I think right now I don't see much difference in that respect in the last two years, in COVID and non-COVID vaccines. Our primary care business is doing quite well, because we have medicines that are doing very well, doing extremely well. Don't forget, we are a superpower when it comes to primary care. Pfizer's primary care business has been the best in the U.S. for the 7th year consecutively. The reasons we are so optimistic also include our acquisition, because we are coming into the market with a very strong, very good product. It's going to be a product that will be once per month instead of once per week. We are really excited to launch in 2028, two years from now.
9 more exchanges in this transcript
Sign in free to read the rest of this interview. No card required.
Bourla, A. (2026, July 4). 'CROWN JEWEL': Pfizer CEO touts 'TREMENDOUS SUCCESSES' in oncology R&D [Interview transcript]. Fox Business. CEOInterviews.AI. https://ceointerviews.ai/interview/1061405/
MLA
Albert Bourla. "'CROWN JEWEL': Pfizer CEO touts 'TREMENDOUS SUCCESSES' in oncology R&D." Fox Business, 4 Jul. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/1061405/.
BibTeX
@misc{bourla2026_1061405,
author = {Albert Bourla},
title = {'CROWN JEWEL': Pfizer CEO touts 'TREMENDOUS SUCCESSES' in oncology R\&D},
howpublished = {Interview transcript, Fox Business. CEOInterviews.AI},
year = {2026},
month = {jul},
url = {https://ceointerviews.ai/interview/1061405/},
note = {Speaker-attributed transcript with timestamps}
}
